BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35412712)

  • 1. [Anaplastic pleomorphic xanthoastrocytoma - single-center analysis of 42 patients].
    Belyaev AY; Shugai SV; Kobyakov GL; Strunina YV; Batalov AI; Pronin IN; Usachev DY
    Zh Vopr Neirokhir Im N N Burdenko; 2022; 86(2):45-54. PubMed ID: 35412712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of
    Huang W; Cai J; Lin N; Xu Y; Wang H; Wu Z; Kang D
    AJNR Am J Neuroradiol; 2021 Dec; 42(12):2152-2159. PubMed ID: 34725042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma.
    Wang J; Liu Z; Cui Y; Liu Y; Fang J; Xu L; He Y; Du J; Su Y; Zou W; Xu Z; Li G
    J Neurooncol; 2019 Aug; 144(1):137-146. PubMed ID: 31214915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
    Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G
    Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study.
    Ma C; Feng R; Chen H; Hameed NUF; Aibaidula A; Song Y; Wu J
    World Neurosurg; 2018 Dec; 120():e1225-e1233. PubMed ID: 30240866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.
    Tabouret E; Bequet C; Denicolaï E; Barrié M; Nanni I; Metellus P; Dufour H; Chinot O; Figarella-Branger D
    Eur J Surg Oncol; 2015 Dec; 41(12):1685-90. PubMed ID: 26454767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
    Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
    J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF Inhibition in
    Kaley T; Touat M; Subbiah V; Hollebecque A; Rodon J; Lockhart AC; Keedy V; Bielle F; Hofheinz RD; Joly F; Blay JY; Chau I; Puzanov I; Raje NS; Wolf J; DeAngelis LM; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM
    J Clin Oncol; 2018 Dec; 36(35):3477-3484. PubMed ID: 30351999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges of targeting
    Smith-Cohn M; Davidson C; Colman H; Cohen AL
    CNS Oncol; 2019 Dec; 8(4):CNS48. PubMed ID: 31818130
    [No Abstract]   [Full Text] [Related]  

  • 10. BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma.
    Lukas RV; Merrell RT
    CNS Oncol; 2018 Apr; 7(2):CNS10. PubMed ID: 29708404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.
    Brown NF; Carter T; Mulholland P
    CNS Oncol; 2017 Jan; 6(1):5-9. PubMed ID: 27781490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
    Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
    Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma.
    Amayiri N; Swaidan M; Al-Hussaini M; Halalsheh H; Al-Nassan A; Musharbash A; Tabori U; Hawkins C; Bouffet E
    J Pediatr Hematol Oncol; 2018 Aug; 40(6):478-482. PubMed ID: 29200156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.
    Ida CM; Rodriguez FJ; Burger PC; Caron AA; Jenkins SM; Spears GM; Aranguren DL; Lachance DH; Giannini C
    Brain Pathol; 2015 Sep; 25(5):575-86. PubMed ID: 25318587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF/MEK Dual Inhibitors Therapy in Progressive and Anaplastic Pleomorphic Xanthoastrocytoma: Case Series and Literature Review.
    Kata K; Rodriguez-Quintero JC; Arevalo OD; Zhang JJ; Bhattacharjee MB; Ware C; Dono A; Riascos-Castaneda R; Tandon N; Blanco A; Esquenazi Y; Ballester LY; Amsbaugh M; Day AL; Zhu JJ
    J Natl Compr Canc Netw; 2022 Nov; 20(11):1193-1202.e6. PubMed ID: 36351333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
    Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A
    Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF V600E-mutated central nervous system tumor with divergent morphological feature - Anaplastic pleomorphic xanthoastrocytoma-like and astroblastoma-like.
    Purkait S; Bansal S; Malgulwar PB
    Neuropathology; 2019 Feb; 39(1):64-67. PubMed ID: 30557911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined pleomorphic xanthoastrocytoma-ganglioglioma with BRAF V600E mutation: case report.
    Cicuendez M; Martinez-Saez E; Martinez-Ricarte F; Asanza EC; Sahuquillo J
    J Neurosurg Pediatr; 2016 Jul; 18(1):53-7. PubMed ID: 27015517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pleomorphic Xanthoastrocytoma: a single institution retrospective analysis and a review of the literature.
    Detti B; Scoccianti S; Maragna V; Lucidi S; Ganovelli M; Teriaca MA; Caini S; Desideri I; Agresti B; Greto D; Buccoliero AM; Puppa AD; Sardi I; Livi L
    Radiol Med; 2022 Oct; 127(10):1134-1141. PubMed ID: 35951279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma.
    Pratt D; Camelo-Piragua S; McFadden K; Leung D; Mody R; Chinnaiyan A; Koschmann C; Venneti S
    Acta Neuropathol Commun; 2018 Mar; 6(1):24. PubMed ID: 29544532
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.